Featured Publications
Neoantigens in Patients with De Novo Follicular Lymphoma: Results from the PRIMA Study
Henneges C, Jin D, Venstrom J, Trabucco S, Nielsen T, Penuel E, Huet S, Salles G, Paulson J. Neoantigens in Patients with De Novo Follicular Lymphoma: Results from the PRIMA Study. Blood 2020, 136: 25-26. DOI: 10.1182/blood-2020-134795.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaDe novo diffuse large B-cell lymphomaProgression-free survivalTumor mutational burdenComprehensive genomic profilingCurrent equity holderAssociated with progression-free survivalFollicular lymphomaF. Hoffmann-La RocheFoundation MedicinePrognostic valueClinical outcomesMedian tumor mutation burdenProgression-free survival eventsPooled analysis of patientsLarge B-cell lymphomaResponse to induction treatmentCalculate tumor mutational burdenAssociated with clinical outcomesEZH2 mutation statusComprehensive genomic profiling dataB-cell lymphomaGenetic mutational landscapeAnalysis of patientsProportion of patients
2020
Automated Baseline Fluorodeoxyglucose-Positron Emission Tomography Imaging and High BCL2 Expression Provide Orthogonal Prognostic Value in Predicting High-Risk De Novo Diffuse Large B-Cell Lymphoma Patients
Jemaa S, Tracy S, Bottos A, de Crespigny A, Bengtsson T, Nielsen T, Paulson J. Automated Baseline Fluorodeoxyglucose-Positron Emission Tomography Imaging and High BCL2 Expression Provide Orthogonal Prognostic Value in Predicting High-Risk De Novo Diffuse Large B-Cell Lymphoma Patients. Blood 2020, 136: 8-9. DOI: 10.1182/blood-2020-134780.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaDiffuse large B-cell lymphoma patientsCurrent equity holderInternational Prognostic IndexTotal metabolic tumor volumeFluorodeoxyglucose-positron emission tomographyF Hoffmann-La RocheArea under the receiver operating characteristic curveR-CHOPPrognostic valueClinical featuresFluorodeoxyglucose-positron emission tomography imagingBCL2 expressionAssociated with reduced PFSInternational Prognostic Index categoryPrognostic value of Bcl2F. Hoffmann-La RocheB-cell lymphoma patientsLarge B-cell lymphomaCell of origin (COOMultivariable Cox-pH modelsPrognostic modelUnivariate Cox proportional hazardsBaseline imaging featuresMetabolic tumor volumeA Prognostic Model Incorporating Tumor Lesion Morphology and Texture Features Identifies High-Risk Patient Subpopulations in De Novo DLBCL and FL
Li X, Jemaa S, Carano R, Bengtsson T, Paulson J, Jansen G, Nielsen T, Hibar D. A Prognostic Model Incorporating Tumor Lesion Morphology and Texture Features Identifies High-Risk Patient Subpopulations in De Novo DLBCL and FL. Blood 2020, 136: 28. DOI: 10.1182/blood-2020-134877.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaProgression-free survivalCurrent equity holderInternational Prognostic IndexFDG-PET scansProgression-free survival probabilityLow-risk groupHigh-risk groupBaseline FDG-PET scanHigh-risk patientsPredicting high-risk patientsFollicular lymphomaFL patientsPrognostic performanceF. Hoffmann-La RocheRadiomic featuresCHOP chemotherapyGALLIUM studyStratify patientsDe novo diffuse large B-cell lymphomaDLBCL populationDiffuse large B-cell lymphoma patientsHigh-risk patient subpopulationsInternational Prognostic Index modelLarge B-cell lymphomaLymphoma Microenvironment Deconvolution Links M1 Macrophage Infiltration to Clinical Outcome in Diffuse Large B-Cell Lymphoma
Yan M, Chang Y, Raghavan V, Dong E, Klein C, Nielsen T, Paulson J, Hatzi K. Lymphoma Microenvironment Deconvolution Links M1 Macrophage Infiltration to Clinical Outcome in Diffuse Large B-Cell Lymphoma. Blood 2020, 136: 29-30. DOI: 10.1182/blood-2020-134867.Peer-Reviewed Original ResearchProgrammed death-ligand 1Current equity holderMacrophage infiltrationM1 macrophagesF. Hoffmann-La RocheLymphoma microenvironmentMacrophage scoreMacrophage signatureClinical outcomesProgrammed death-ligand 1 mRNA expressionDiffuse large B-cell lymphomaNatural killer (NK) cellsAssociated with shorter PFSCD20-targeted monoclonal antibodyNK cell-mediated ADCCPrognostic trendTreatment outcomesLarge B-cell lymphomaRecruitment of M1 macrophagesPhase III clinical trialsImmune microenvironment profilesInternational Prognostic IndexResponse to immunochemotherapyDeath-ligand 1Improved overall survivalTRAIL (Tolerability of R-CHOP in Aggressive non-Hodgkin Lymphoma): A Predictive Algorithm to Support Clinical Decision-Making
Bataillard E, Harris W, El-Galaly T, Kwan A, Henneges C, Paulson J, Nielsen T. TRAIL (Tolerability of R-CHOP in Aggressive non-Hodgkin Lymphoma): A Predictive Algorithm to Support Clinical Decision-Making. Blood 2020, 136: 34-35. DOI: 10.1182/blood-2020-134904.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaCurrent equity holderArea under the receiver operating characteristic curveAverage relative dose intensityCharlson Comorbidity IndexBone marrow lymphocytesR-CHOPAnti-CD20Progressive diseaseWithdrawal of cyclophosphamideAdverse eventsMarrow lymphocytesDiffuse large B-cell lymphoma patientsLong-term event free survivalTreatment of diffuse large B-cell lymphomaClinical trialsDose intensity of cyclophosphamideProportion of Th cellsTreated with R-CHOPF. Hoffmann-La RocheHigh risk of relapseLarge B-cell lymphomaAlternative therapiesR-CHOP treatmentRelative dose intensity